Bristol-Myers’ Phase 2 Alpha-Thalassemia Data Show Hemoglobin Gains, Fewer Transfusions
Bristol-Myers released topline Phase 2 data showing Reblozyl raised hemoglobin significantly in non-transfusion-dependent adults with alpha-thalassemia and cut transfusion burden in transfusion-dependent patients while meeting all key secondary endpoints. Safety aligned with known profiles, and results will be presented at a medical congress with regulatory discussions slated in China.
1. Phase 2 Study Outcomes
Bristol-Myers’ Phase 2 trial tested Reblozyl in adults with alpha-thalassemia, achieving primary endpoints with a statistically significant rise in mean hemoglobin levels for non-transfusion-dependent patients and a notable reduction in red blood cell transfusions for transfusion-dependent patients, while all key secondary endpoints were met.
2. Presentation and Regulatory Plans
The company plans to present detailed results at an upcoming medical congress and is preparing discussions with China’s Center for Drug Evaluation to advance potential approval in the Chinese market and other regions.
3. Market Response and Analyst Ratings
Shares have gained roughly 30% over the past 12 months but are trading 2.5% below the 20-day and 3.8% below the 100-day simple moving averages; analysts maintain a hold consensus with an average price target of $60.10, while Piper Sandler and Barclays have raised targets to $75 and Citigroup to $64.